Enoch accelerates expansion in China

Wen/Our correspondent Zheng Lijie Global Diabetes Leading Enterprise Connaught and Connaught (China) Pharmaceutical Co., Ltd. recently announced that due to the rapid development of China's diabetes market and the needs of global business strategy, Connaught and Connaught Greater China will be upgraded to an independent region, reporting directly to the Danish headquarters.　　The company will also invest more in China, expanding its research and development center in Beijing by one-fold over the next 3-5 years.　　According to reports, from January 1, 2011 onwards, Connaught and Connaught Greater China will be upgraded to an independent region, directly to the Danish headquarters reporting, as the North America, Europe, Japan-Korea and international operations in line with the world's 5 business groups. "China is one of the fastest growing pharmaceutical markets in the world, while China's diabetes market is growing fast," he said. For Enoch and Enoch, this has two meanings. On the one hand, the great potential of China's diabetes market has become increasingly important in its global strategy. And on the other hand, as a ' change diabetes '-minded enterprise, in the face of China's increasingly severe diabetes status, Connaught and Connaught have the responsibility to increase investment in China to help China better meet the challenges of diabetes. The upgrading of greater China is an important milestone for Connaught and Connaught to strengthen its development strategy in China, as well as its confidence and determination in the future development of the Chinese market.　　"says Mr Schultz, executive vice president and global chief operating officer of Connaught and Connaught. It is reported that this move did not give Connaught and Germany Greater China's internal management structure to bring great adjustment, the former Greater China president Corrillon will continue to be fully responsible for greater China business expansion. "With the upgrading of the Greater China region, our communication with headquarters will be smoother and will receive more direct and strong support from Headquarters," he said. At the same time, the headquarters will be more aware of the changes in the Chinese market and demand, to develop a more relevant to the characteristics of China's market development strategy, so as to achieve changes in China's current status of diabetes ambitious goals. As the head of business in Greater China, I have confidence in the future of Connaught and Connaught in China.　　"Corrillon said. With the upgrading of Greater China, Connaught and Connaught will also increase their investment in China, in the next 3-5 years, the development center in Beijing to expand the scale of one-fold. At that time, its new plant in Tianjin will be fully put into production. "Innovation is Connaught and Connaught German Enterprise development Intrinsic power, China has first-class research and development talent and rich clinical resources, increase in China's research and development investment, is to maintain the long-term development of the company, but also to help China to improve clinical research and development level, the realization of corporate growth and social responsibility of the important strategy. "Yebo, global chief financial officer of Connaught and Connaught, said. In order to practice its always advocated environmental responsibility, Connaught and Connaught is under construction in Tianjin new plant will strictly implement the green environmental standards, officially put into production, it will be more than the current Connaught and Connaught the most advanced plant energy saving 20%.